Atea Pharmaceuticals, Inc. — Director's Dealing 2020

Oct 30, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2020-10-29

Reporting Person: Lucidi Bruno (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	50000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.24	2026-12-08	Common Stock (75000)		Direct
Stock Option (Right to Buy)	$1.43	2028-12-13	Common Stock (50000)		Direct

Footnotes

F1: The option is fully vested and exercisable.

F2: The option vests and becomes exercisable in 24 equal monthly installments following November 30, 2018.